{
    "Trade/Device Name(s)": [
        "QUANTA Lite PBC Screen IgG/IgA ELISA"
    ],
    "Submitter Information": "INOVA Diagnostics, Inc.",
    "510(k) Number": "K061842",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DBM",
        "NRI",
        "NUM"
    ],
    "Summary Letter Date": "October 18, 2006",
    "Summary Letter Received Date": "June 29, 2006",
    "Submission Date": "June 22, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.5090"
    ],
    "Regulation Name(s)": [
        "Anti-mitochondrial Antibody Immunological Test System"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "mitochondrial antibodies",
        "gp210 antibodies",
        "sp100 antibodies"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)"
    ],
    "Methodologies": [
        "ELISA"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for QUANTA Lite PBC Screen IgG/IgA ELISA for detection of mitochondrial, gp210, and sp100 antibodies in human serum",
    "Indications for Use Summary": "Semi-quantitative detection of mitochondrial, gp210, and sp100 antibodies of IgG/IgA class in human serum to aid in the diagnosis of primary biliary cirrhosis, used in conjunction with clinical findings and other laboratory tests.",
    "fda_folder": "Immunology"
}